Monthly PFI-2 Wrap Up Is Starting To Really Feel Slightly Out Of Date

001) (Fig. 2). Median progression-free survival was 7 months for the young patients, compared with 13 months in the older patient group. Disease-free survival rates after 3 and 5 years were 25% and 17% in the young patient group, versus 34% and 23% in the older patients (median, 18 months vs 19 months; P = .10) (Fig. 3). The difference http://www.selleckchem.com/products/epacadostat-incb024360.html between progression-free and disease-free survival rates is illustrated in Figure 4. At multivariate analysis, 7 factors emerged as independent predictors of poor overall survival: primary tumor located in the right colon, ��3 liver metastases at diagnosis, the presence of concomitant extrahepatic disease, administration of preoperative chemotherapy, preoperative carcinoembryonic antigen (CEA) level ��5 ng/mL, preoperative portal vein embolization, and maximum size of liver metastases ��30 mm at histopathologic examination (Table 5). For progression-free survival, the following poor predictors were identified: age at hepatectomy ��40 years, administration of preoperative chemotherapy, preoperative CEA level ��5 ng/mL, ��3 liver metastases detected by intraoperative ultrasound, major hepatectomy, nonanatomical hepatic resection, and the administration http://www.selleckchem.com/products/MG132.html of postoperative chemotherapy (Table 6). Long-term outcomes after hepatic resection for colorectal liver metastases in young patients are still unknown. This was the impetus for the current study, evaluating long-term outcomes in patients ��40 years old, which were compared with patients older than 40 years. Within the current study, young patients presented with more extensive disease, reflected by a higher number of metastases, which were more often diagnosed synchronous with the primary tumor. Furthermore, overall survival rates tended to be lower in the young patient group (5-year overall survival rate, 33% vs 51%; P = .12). Also, young patients more often developed a disease http://www.selleck.cn/products/pfi-2.html recurrence (88% vs 69%, P = .003), and progression-free survival in this patient group was significantly lower than that observed for older patients (5-year progression-free survival rate, 2% vs 16%; P